



Challenges in Cellular Immunotherapy in Cancer Treatment

Guest Editor:

Dr. Lydia Meder

1. Department I of Internal
Medicine, University Hospital
Cologne, 50937 Cologne,
Germany

2. Center for Molecular Medicine
Cologne, University of Cologne,
50937 Cologne, Germany

Deadline for manuscript
submissions:

closed (30 September 2022)

Message from the Guest Editor

Cell-based cancer therapies are continuously evolving and improving, not only in the treatment of hematologic malignancies but also in solid tumors. Prominent cellular cancer therapies comprise T cell-based and natural killer (NK) cell-based therapies engineered with synthetic chimeric antigen receptors (CARs). Based on your expertise in cellular immunotherapy, you are invited to contribute a research paper or review in this Special Issue to highlight the remaining challenges for clinicians: to achieve a maximal, selective and persisting anti-tumor immune response in patients suffering from rapidly progressive cancers. Studies focusing on B cell-based and DC-based immunotherapy, and pre-clinical investigations are also welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)